Cargando…

Retrospective Study of the Safety and Efficacy of Anlotinib Combined With Dose-Dense Temozolomide in Patients With Recurrent Glioblastoma

PURPOSE: The purpose of this study was to retrospectively analyze the safety and clinical efficacy of anlotinib combined with dose-dense temozolomide (TMZ) as the first-line therapy in the treatment of recurrent glioblastoma (rGBM). PATIENTS AND METHODS: We collected the clinical data of 20 patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	She, Lei, Su, Lin, Shen, Liangfang, Liu, Chao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330423/ https://www.ncbi.nlm.nih.gov/pubmed/34354945 http://dx.doi.org/10.3389/fonc.2021.687564

Ejemplares similares

Anlotinib Alone or in Combination With Temozolomide in the Treatment of Recurrent High-Grade Glioma: A Retrospective Analysis
por: Yang, Qunying, et al.
Publicado: (2021)

Almonertinib Combined with Anlotinib and Temozolomide in a Patient with Recurrent Glioblastoma with EGFR L858R Mutation
por: Hou, Zhiwei, et al.
Publicado: (2023)

Bevacizumab combined with re-irradiation in recurrent glioblastoma
por: She, Lei, et al.
Publicado: (2022)

Radiotherapy Plus Temozolomide With or Without Nimotuzumab Against the Newly Diagnosed EGFR-Positive Glioblastoma: A Retrospective Cohort Study
por: She, Lei, et al.
Publicado: (2022)

Apatinib Plus Temozolomide: An Effective Salvage Treatment for Recurrent Glioblastoma
por: Ge, Jingjing, et al.
Publicado: (2021)

Clinical and economic evaluation of modulated electrohyperthermia concurrent to dose-dense temozolomide 21/28 days regimen in the treatment of recurrent glioblastoma: a retrospective analysis of a two-centre German cohort trial with systematic comparison and effect-to-treatment analysis
por: Roussakow, Sergey V
Publicado: (2017)

Efficacy and safety of anlotinib-based treatment in metastatic breast cancer patients
por: Qian, Yu, et al.
Publicado: (2022)

The efficacy and adverse effects of anlotinib in the treatment of high-grade glioma: A retrospective analysis
por: Shen, Fangcheng, et al.
Publicado: (2023)

The Definition and Delineation of the Target Area of Radiotherapy Based on the Recurrence Pattern of Glioblastoma After Temozolomide Chemoradiotherapy
por: Zheng, Lin, et al.
Publicado: (2021)

Efficacy and safety of anlotinib plus programmed death-1 blockade versus anlotinib monotherapy as second or further-line treatment in advanced esophageal squamous cell carcinoma: A retrospective study
por: Liu, Ying, et al.
Publicado: (2022)

Dose-dense Temozolomide: Is It Still Promising?
por: NAGANE, Motoo
Publicado: (2015)

Safety and Efficacy of Hypofractionated Stereotactic Radiotherapy with Anlotinib Targeted Therapy for Glioblastoma at the First Recurrence: A Preliminary Report
por: Guan, Yun, et al.
Publicado: (2022)

Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study
por: Taal, Walter, et al.
Publicado: (2012)

Survival analysis of HDR brachytherapy versus reoperation versus temozolomide alone: a retrospective cohort analysis of recurrent glioblastoma multiforme
por: Archavlis, Eleftherios, et al.
Publicado: (2013)

Extended adjuvant temozolomide in newly diagnosed glioblastoma: A single-center retrospective study
por: Chen, Jie, et al.
Publicado: (2022)

Continuous Low-Dose Temozolomide Chemotherapy and Microvessel Density in Recurrent Glioblastoma
por: Woo, Jong-Yun, et al.
Publicado: (2015)

Anlotinib combined with temozolomide suppresses glioblastoma growth via mediation of JAK2/STAT3 signaling pathway
por: Xu, Peng, et al.
Publicado: (2022)

Continuous dose-intense temozolomide and cisplatin in recurrent glioblastoma patients
por: Wang, Yu, et al.
Publicado: (2017)

Real-World Efficacy and Safety of Anlotinib With and Without Immunotherapy in Advanced Non-Small Cell Lung Cancer
por: Xiong, Qi, et al.
Publicado: (2021)

Efficacy and Safety of Anlotinib in the Treatment of Small Cell Lung Cancer: A Real-World Observation Study
por: Yuan, Jing, et al.
Publicado: (2022)

Integrins and p53 pathways in glioblastoma resistance to temozolomide
por: Martin, Sophie, et al.
Publicado: (2012)

The Efficacy and Safety of Anlotinib Alone and in Combination with Other Drugs in Previously Treated Advanced Thymic Epithelia Tumors: A Retrospective Analysis
por: Li, Shuo, et al.
Publicado: (2023)

Clinical Activity and Safety of Penpulimab (Anti-PD-1) With Anlotinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: An Open-Label, Multicenter, Phase Ib/II Trial (AK105-203)
por: Han, Chun, et al.
Publicado: (2021)

Extended-schedule dose-dense temozolomide in refractory gliomas
por: Berrocal, A., et al.
Publicado: (2009)

Anlotinib Combined With Chemoradiotherapy Exhibits Significant Therapeutic Efficacy in Esophageal Squamous Cell Carcinoma
por: Shi, Jingzhen, et al.
Publicado: (2020)

The Efficacy and Safety of Anlotinib in Pediatric Patients With Refractory or Recurrent Solid Tumors
por: Lu, Suying, et al.
Publicado: (2022)

A multicenter, phase 1, dose escalation clinical trial (G-FORCE-1) of XRT, RRx-001 and temozolomide followed by temozolomide +/- RRx-001 in newly diagnosed glioblastoma
por: Fine, Howard, et al.
Publicado: (2023)

Efficacy of Anlotinib for the Treatment of Angiosarcoma of the Face and Neck: A Case Report
por: Ren, Biyong, et al.
Publicado: (2021)

An overview of glioblastoma multiforme and temozolomide resistance: can LC-MS-based proteomics reveal the fundamental mechanism of temozolomide resistance?
por: Teraiya, Milan, et al.
Publicado: (2023)

The Current Role of Adjuvant Chemotherapy in Locally Advanced Nasopharyngeal Carcinoma
por: Su, Lin, et al.
Publicado: (2021)

Corrigendum: Anlotinib Combined With Chemoradiotherapy Exhibits Significant Therapeutic Efficacy in Esophageal Squamous Cell Carcinoma
por: Shi, Jingzhen, et al.
Publicado: (2020)

Anlotinib for the Treatment of Multiple Recurrent Lumbar and Sacral Cord Hemangioblastomas: A Case Report
por: Jin, Nan, et al.
Publicado: (2022)

Efficacy and safety of anlotinib in metastatic adenoid cystic carcinoma: a retrospective study
por: Su, Ning, et al.
Publicado: (2022)

Organized Pneumonia Secondary to Increasing Doses of Temozolomide
por: Marcos, Pedro J, et al.
Publicado: (2015)

LAPTM5–CD40 Crosstalk in Glioblastoma Invasion and Temozolomide Resistance
por: Berberich, Anne, et al.
Publicado: (2020)

Identifying Predictive Gene Expression and Signature Related to Temozolomide Sensitivity of Glioblastomas
por: Cai, Hong-Qing, et al.
Publicado: (2020)

Diffusing alpha-emitters radiation therapy in combination with temozolomide or bevacizumab in human glioblastoma multiforme xenografts
por: Nishri, Yossi, et al.
Publicado: (2022)

The Efficacy and Safety of Anlotinib Combined With PD-1 Antibody for Third-Line or Further-Line Treatment of Patients With Advanced Non-Small-Cell Lung Cancer
por: Zhai, Chongya, et al.
Publicado: (2021)

Efficacy and Safety of Anti-PD-1 Plus Anlotinib in Patients With Advanced Non–Small-Cell Lung Cancer After Previous Systemic Treatment Failure—A Retrospective Study
por: Wang, Peiliang, et al.
Publicado: (2021)

Anlotinib for Recurrent or Metastatic Primary Malignant Bone Tumor: A Multicenter, Single-Arm Trial
por: Tang, Lina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_puoj3t802nt6gl2ncfr2qvdra1